United States
Pramipexole CAS NO.191217-81-9
- Min.Order: 0 Metric Ton
- Payment Terms: T/T,MoneyGram
- Product Details
Keywords
- Pramipexole Dihydrochloride
- Pharmaceutical Intermediate
- Pharmaceutical Chemicals
Quick Details
- ProName: Pramipexole
- CasNo: 191217-81-9
- Application: sexual dysfunction
- DeliveryTime: Withn 4 days
- PackAge: alluminum foil bag
- Port: Any
- ProductionCapacity: Metric Ton/Day
- Purity: 99%
- LimitNum: 0 Metric Ton
Superiority
Pramipexole
1,keywords:Pramipexole,Pramipexole hcl,Pramipexole 2HCL monohydrate (CAS: 191217-81-9 )
Pramipexole (CAS: 104632-26-0 )
Pramipexole Dihydrochloride (CAS: 104632-25-9)
2,info:
| Products: | Pramipexole |
| Cas No. | 191217-81-9 |
| Molecular Formula | C10H21Cl2N3OS |
| Molecular Weight | 302.26 |
| Assay | 99% |
| Package | 100g,1kg, 5kg, 10kg,25KG |
3,Function:
General introduction:Pramipexole dihydrochloride is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) andrestless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia.
Details
Pramipexole
1,keywords:Pramipexole,Pramipexole hcl,Pramipexole 2HCL monohydrate (CAS: 191217-81-9 )
Pramipexole (CAS: 104632-26-0 )
Pramipexole Dihydrochloride (CAS: 104632-25-9)
2,info:
| Products: | Pramipexole |
| Cas No. | 191217-81-9 |
| Molecular Formula | C10H21Cl2N3OS |
| Molecular Weight | 302.26 |
| Assay | 99% |
| Package | 100g,1kg, 5kg, 10kg,25KG |
3,Function:
General introduction:Pramipexole dihydrochloride is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) andrestless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia.